Patents Examined by James D. Anderson
  • Patent number: 11116773
    Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: September 14, 2021
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 11116724
    Abstract: A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: September 14, 2021
    Assignee: Rosemount Pharmaceuticals Ltd
    Inventors: Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
  • Patent number: 11110073
    Abstract: The present invention relates to a stable, aqueous, injectable solution comprising diclofenac and polyvinylpyrrolidone. The present invention also relates to processes for preparing the injectable solution.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 7, 2021
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Sushilkumar Dhanaji Patil, Nirav Ishwarlal Khatri, Alex Kochukunju George, Sushrut Krishnaji Kulkarni
  • Patent number: 11103580
    Abstract: Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: August 31, 2021
    Assignee: Immunolight, LLC
    Inventor: Frederic A. Bourke, Jr.
  • Patent number: 11096927
    Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 24, 2021
    Assignees: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
  • Patent number: 11077089
    Abstract: Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: August 3, 2021
    Assignee: Per Os Biosciences, LLC
    Inventors: Robert Estey, William O. Brisben
  • Patent number: 11071737
    Abstract: A pharmaceutical composition comprises an active component KX2-361 represented by formula 1 or a medicinal salt thereof and hydroxylpropoxyl-?-cyclodextrin. An inclusion compound is formed by KX2-361 or the medicinal salt thereof and hydroxylpropoxyl-?-cyclodextrin, and the solubility of the poorly-soluble drug KX2-361 is improved. The pharmaceutical composition can be prepared into an intravenous preparation and an oral preparation.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: July 27, 2021
    Assignee: GUANGZHOU XIANGXUE PHARMACEUTICAL CO., LTD.
    Inventors: Shuiping Shi, Qingyong Zhang, Ronghua Zhao, Huihong Chen, Lun Zeng, Daxin Ou, Yan Liu
  • Patent number: 11053552
    Abstract: Described herein are methods that define cellular populations that are sensitive to RARA agonists and identify patient populations that will benefit from treatment with RARA agonists. The methods may comprise administering RARA agonists to patient populations.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: July 6, 2021
    Assignee: Syros Pharmaceuticals, Inc.
    Inventors: Michael Robert McKeown, Christopher Fiore, Matthew Lucas Eaton, Emily Payton Lee, Christian Fritz
  • Patent number: 11040048
    Abstract: A medicament characterized in that (A) a compound represented by the formula (I): its pharmaceutically acceptable salt, or a solvate thereof, wherein P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4 is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A are each independently hydrogen, halogen, alkyl, or the like; R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; n is any integer of 1 to 2; and R1 is or the like, is combined
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 22, 2021
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takao Shishido, Takeshi Noshi, Atsuko Yamamoto, Mitsutaka Kitano
  • Patent number: 11026896
    Abstract: Disclosed herein is a transdermal delivery formulation for transdermal delivery of a Cannabidiol, with or without one or more additional active agents through the dermis, including the skin, nail or hair follicle of a subject, wherein the formulation comprises a) a transdermal delivery formulation in an amount less than about 60% w/w, comprising i. one or more phosphatides, ii. glucose, and iii. one or more fatty acids; b) water in an amount less than about 50% w/w, a Cannabidiol with or within one or more additional active agents.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: June 8, 2021
    Assignee: DYVE BIOSCIENCES, INC.
    Inventors: Nathan Fitzsimmons, Ryan Beal, Audrene McMahon, Brandon Sand, Kilmar Martinez
  • Patent number: 11026926
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: June 8, 2021
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Patent number: 11021459
    Abstract: The present technology is directed to d-threo-methylphenidate conjugates and a composition comprising d-threomethylphenidate conjugated to nicotinoyl-L-serine, or salt thereof. The present technology also relates to a composition comprising at least one conjugate of d-methylphenidate having at least two or more chiral centers. The composition is optically active. The present technology additionally relates to oral formulations and pharmaceutical kits comprising at least one d-threo-methylphenidate conjugate. The pharmaceutical kit may comprise a specified amount of individual doses in a package. Each individual dose in the package may contain a pharmaceutically effective amount of a conjugate of d-threo methylphenidate.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: June 1, 2021
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi
  • Patent number: 11020372
    Abstract: The invention relates to novel methods and compositions for safely reducing negative side effects of cancer treatments. These methods and compositions comprise administering to a patient a composition comprising one or more of the following: curcumin (derived from turmeric), epigallocatechin-3-gallate (EGCG, enriched in green tea), glucosinolates (enriched in cruciferous vegetables) and/or derivatives thereof, such as sulforaphane (SFN), alone or combined with a ketogenic diet or a modified ketogenic diet. Also the current invention relates to a composition comprising medium chain triglycerides (MCT), Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as sulforaphane (SFN).
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: June 1, 2021
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Loic Pierre Deleyrolle, Brent Allan Reynolds
  • Patent number: 11021460
    Abstract: The present technology is directed to d-threo-methylphenidate conjugates and a composition comprising d-threomethylphenidate conjugated to nicotinoyl-L-serine, or salt thereof. The present technology also relates to a composition comprising at least one conjugate of d-methylphenidate having at least two or more chiral centers. The composition is optically active. The present technology additionally relates to oral formulations and pharmaceutical kits comprising at least one d-threo-methylphenidate conjugate. The pharmaceutical kit may comprise a specified amount of individual doses in a package. Each individual dose in the package may contain a pharmaceutically effective amount of a conjugate of d-threo methylphenidate.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: June 1, 2021
    Assignee: KemPharm, Inc.
    Inventors: Travis Mickle, Sven Guenther, Guochen Chi
  • Patent number: 11020385
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: June 1, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Patent number: 11007141
    Abstract: An oral preparation for treating cell proliferation diseases. The oral preparation comprises hydroxylpropoxyl-?-cyclodextrin and an active component. The active component is KX2-361 or a medicinal salt thereof, and KX2-361 is represented by formula 1. By mixing hydroxylpropoxyl-ydcyclodextrin with KX2-361 or the medicinal salt thereof, an inclusion complex is formed, the solubility of the poorly-soluble drug KX2-361 is greatly improved, and accordingly the drug is prepared into an oral preparation. The oral preparation has good stability, high safety, good absorbability, high bioavailability and economical cost.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: May 18, 2021
    Assignees: GUANGZHOU XIANGXUE PHARMACEUTICAL CO., LTD., HANGZHOU CONVERD CO., LTD.
    Inventors: Shuiping Shi, Qingyong Zhang, Ronghua Zhao, Huihong Chen, Lun Zeng, Daxin Ou, Yan Liu
  • Patent number: 11001600
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors of Factor D described herein reduce the excessive activation of complement, and are useful to treat disorders mediated by the complement system.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 11, 2021
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • Patent number: 10973811
    Abstract: Novel pharmaceutical compositions including cocaine hydrochloride and methods of treating patients using those pharmaceutical compositions are described.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: April 13, 2021
    Assignee: GENUS LIFESCIENCES INC.
    Inventors: Jeffrey M. Moshal, Michael Libman
  • Patent number: 10973777
    Abstract: The present application relates to methods and uses of CB2 target agent local anesthetics such as beta-caryophyllene for treatment of interstitial cystitis in a subject, optionally together with the administration or use of an additional agent for treating interstitial cystitis such as dimethyl sulfoxide (DMSO) or methylsulfonylmethane (MSM).
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: April 13, 2021
    Assignee: Panag Pharma Inc.
    Inventors: Melanie Kelly, Christian Lehmann, Mary Lynch
  • Patent number: 10973814
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: April 13, 2021
    Assignee: HIKMA PHARMACEUTICALS USA INC.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda